This partnership, that involves Ohio University’s schools of Arts and Sciences, Health insurance and Human Solutions and Osteopathic Medicine, is made to encourage and support disadvantaged and minority students interested in health medicine and careers, beginning at CSCC and extending to Ohio University if they transfer. ‘This agreement puts in place a process to target Columbus State students who are pursuing health-related professions and, through Pathways Institute Partnership, provide support, mentoring and career guidance to help them satisfy their goals. It is usually anticipated that many of the college students will transfer to Ohio University to total their undergraduate degrees in the schools of Arts and Sciences, and Health and Human Services, and that some of those interested in attending medical school shall apply to the faculty of Osteopathic Medicine,’ said Elizabeth Small, director of the guts for Excellence for Multicultural Medication at Ohio University.Arnold, M.D., Amit Bar-Or, M.D., Gavin Giovannoni, M.D., Krzysztof Selmaj, M.D., Carlo Tornatore, M.D., Marianne T. Sweetser, M.D., Ph.D., Minhua Yang, M.S., Sarah I. Sheikh, M.D., and Katherine T. Dawson, M.D. For the DEFINE Research Investigators: Placebo-Controlled Phase 3 Research of Oral BG-12 for Relapsing Multiple Sclerosis Oral BG-12 has been investigated for the treating multiple sclerosis. Inflammation and oxidative tension are central pathologic factors in multiple sclerosis.1,2 Immune cell activation and infiltration in to the central nervous system are thought to bring about widespread cellular damage, potentially due to the dysregulated production and discharge of reactive oxygen and nitrogen species, such as hydrogen peroxide and peroxynitrite, and proinflammatory stimuli.3 This combination of toxic factors ultimately effects in demyelination and neurodegeneration, leading to disease activity and progression of disability.1,4 BG-12 might also play a role in modulating immune-cell responses by shifting dendritic-cell differentiation,5 suppressing proinflammatory-cytokine production, or directly inhibiting proinflammatory pathways.